MX2021003599A - Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion. - Google Patents

Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.

Info

Publication number
MX2021003599A
MX2021003599A MX2021003599A MX2021003599A MX2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A
Authority
MX
Mexico
Prior art keywords
rpl554
hfa
inhalation
administration
pharmaceutical compositions
Prior art date
Application number
MX2021003599A
Other languages
English (en)
Inventor
Peter Lionel Spargo
Phillip A Haywood
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of MX2021003599A publication Critical patent/MX2021003599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica líquida que es adecuada para la administración mediante inhalación que comprende: (i) una suspensión de partículas que comprenden 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carbamo il-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinolin- 4-ona (RPL554); y (ii) un diluyente el cual es 1,1,1,2-tetrafluoroetano (HFA-134a), en donde la composición farmacéutica líquida está sustancialmente libre de tensioactivo. La invención también se refiere a un inhalador presurizado de dosis medidas que comprende la composición farmacéutica líquida.
MX2021003599A 2018-10-09 2019-10-09 Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion. MX2021003599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
MX2021003599A true MX2021003599A (es) 2021-05-28

Family

ID=64394831

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003599A MX2021003599A (es) 2018-10-09 2019-10-09 Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.
MX2024001499A MX2024001499A (es) 2018-10-09 2021-03-26 Composiciones farmacéuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administración por inhalación.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001499A MX2024001499A (es) 2018-10-09 2021-03-26 Composiciones farmacéuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administración por inhalación.

Country Status (25)

Country Link
US (1) US20210379053A1 (es)
EP (2) EP3960157A1 (es)
JP (2) JP2022513566A (es)
KR (1) KR20210073532A (es)
CN (1) CN112912064A (es)
AU (1) AU2019358585A1 (es)
BR (1) BR112021006712A2 (es)
CA (1) CA3113167A1 (es)
CY (1) CY1124943T1 (es)
DK (1) DK3820446T3 (es)
ES (1) ES2899744T3 (es)
GB (1) GB2578093B (es)
HR (1) HRP20220053T1 (es)
HU (1) HUE057780T2 (es)
IL (1) IL282032A (es)
LT (1) LT3820446T (es)
MX (2) MX2021003599A (es)
PH (1) PH12021550767A1 (es)
PL (1) PL3820446T3 (es)
PT (1) PT3820446T (es)
RS (1) RS62775B1 (es)
SG (1) SG11202102567UA (es)
SI (1) SI3820446T1 (es)
WO (1) WO2020074894A1 (es)
ZA (1) ZA202102039B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
TW202421154A (zh) * 2022-10-28 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種包含異喹啉酮類化合物的醫藥組成物及其製備方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773504B2 (en) 1999-03-31 2004-05-27 Verona Pharma Plc Derivatives of pyrimido(6,1-a)isoquinolin-4-one
RS57075B1 (sr) 2013-03-15 2018-06-29 Verona Pharma Plc Kombinacija leka
RU2688191C2 (ru) * 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
WO2016042313A1 (en) * 2014-09-15 2016-03-24 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
US20210379053A1 (en) 2021-12-09
LT3820446T (lt) 2021-12-10
CA3113167A1 (en) 2020-04-16
GB2578093B (en) 2020-11-18
PL3820446T3 (pl) 2022-03-14
AU2019358585A1 (en) 2021-04-15
CN112912064A (zh) 2021-06-04
BR112021006712A2 (pt) 2021-07-27
ES2899744T3 (es) 2022-03-14
SG11202102567UA (en) 2021-04-29
HRP20220053T1 (hr) 2022-04-15
MX2024001499A (es) 2024-02-27
EP3820446A1 (en) 2021-05-19
WO2020074894A1 (en) 2020-04-16
JP2022513566A (ja) 2022-02-09
IL282032A (en) 2021-05-31
EP3820446B1 (en) 2021-11-03
GB2578093A (en) 2020-04-22
SI3820446T1 (sl) 2022-01-31
DK3820446T3 (da) 2021-12-06
JP2024113096A (ja) 2024-08-21
EP3960157A1 (en) 2022-03-02
PT3820446T (pt) 2021-12-03
RS62775B1 (sr) 2022-01-31
GB201816447D0 (en) 2018-11-28
KR20210073532A (ko) 2021-06-18
ZA202102039B (en) 2022-08-31
CY1124943T1 (el) 2023-01-05
PH12021550767A1 (en) 2021-10-04
HUE057780T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
PH12021550767A1 (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
PH12017500479B1 (en) Liquid inhalation formulation comprising rpl554
MY123544A (en) New inhalable powder containing tiotropium
MX2016013951A (es) Metodo para minimizar el rocio del aerosol usando un sistema de pulverizacion a presion.
MY121073A (en) Pharmaceutical formulations for aerosols with two or more active substances
NZ723838A (en) Cannabinoid compositions and uses
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
MX2013013440A (es) Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
MX2022001724A (es) Composicion farmaceutica que comprende ensifentrina.
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
MX370890B (es) Composición que comprende sulfato de salbutamol.
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
EA201800266A1 (ru) Антивирусная фармацевтическая композиция
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
EP4400119A3 (en) Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
NZ599901A (en) Improved medicinal aerosol formulations
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
MY140890A (en) New tiotropium containing powder formulation for inhalation
MX2022002185A (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso.